Knowledge domain and emerging trends in empagliflozin for heart failure: A bibliometric and visualized analysis.

ABSTRACT:

Objective

Empagliflozin (EMPA), a sodium-glucose cotransporter 2 inhibitor (SGLT2i), is recommended for all patients with Heart failure (HF) to reduce the risk of Cardiovascular death, hospitalization, and HF exacerbation. Qualitative and quantitative evaluation was conducted by searching relevant literatures of EMPA for Heart Failure from 2013 to 2022, and visual analysis in this field was conducted.

Methods

The data were from the Web of Science Core Collection database (WOSCC). The bibliometric tools, CiteSpace and VOSviewer, were used for econometric analysis to probe the evolvement of disciplines and research hotspots in the field of EMPA for Heart Failure.

Results

A total of 1461 literatures with 43861 references about EMPA for Heart Failure in the decade were ex

SUBMITTER: Zhang X 

PROVIDER: S-EPMC9668858 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature